Clinical analysis of primary malignant melanoma of the cervix

Chinese Medical Sciences Journal

Volumn 20, Issue 4, 2005, Pages 257-260

  Ma, Shui Qing ^a   Bai, Chun Mei ^a   Zhong, Sen ^a   Yu, Xiao Hong ^a   Lang, Jing He ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Cervical neoplasms; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; EPIRUBICIN; ETOPOSIDE; GAMMA INTERFERON; IFOSFAMIDE; INTERLEUKIN 2; MONOCLONAL ANTIBODY HMB 45; PACLITAXEL; PROTEIN S 100;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; DEATH; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVAGINAL DRUG ADMINISTRATION; MELANOMA; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; RETROSPECTIVE STUDY; SURVIVAL TIME; SYMPTOM; UTERINE CERVIX CANCER; VAGINA BLEEDING;

ADULT; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; INTERFERON TYPE II; INTERFERON-GAMMA; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; S100 PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 30444432947     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Cobellis L, Calabrese E, Stefanon B, et al. Malignant melanoma of the vagina. A report of 15 cases. Eur J Gynaecol Oncol 2000; 21:295-7.
2. Chua S, Viegas OA, Wee A, et al. Malignant melanomas of the cervix. Gynecol Obstet Invest 1989;27:107-9.
3. Clement PB. Miscellaneous primary tumors and metastatic tumors of the uterine cervix. Semin Diagn Pathol 1990;7:228-48.
4. Bacchi CE, Goldfogel GA, Greer BE, et al. Paget's disease and melanoma of the vulva. Use of a panel of monoclonal antibodies to identify cell type and to microscopically define adequacy of surgical margins. Gynecol Oncol 1992;46:216-21.
5. Wang YJ, Chong WQ, Bu DW. Clinical analysis of primary malignant of the female genital tract in fifteen cases. Chin J Obstet Gynecol 1997;32:226-8.
6. Xing LC. Four cases report of cervical blue nevus. Guangdong Med J 1991;2:29.
7. Liu FS, Liu TH. Pathology of tumor. Beijing: Cooperation Publish House of Beijing Medical University and Peking Union Medical University; 1997.p.1768-75.
8. Pazdur R, Coia LR, Hoskins WJ, et al. Cancer management: a multidisciplinary approach. 7th ed. New York: Ortho Biotech Oncology; 2003.p.528-9.
9. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995;75:726-34.
10. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alpha-2b in high-risk melanoma: first analysis of inter-group trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-58.
11. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6:S11-4.
12. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:1600-7.
13. Kondapalli L, Soltani K, Lacouture ME. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J Am Acad Dermatol 2005; 53:291-302.
14. Voit C, Kron M, Rademaker J, et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005;23:1218-27.